New research may help doctors determine when (and when not) to test for antiglutamate decarboxylase antibodies in patients with neurological disorders and psychiatric symptoms.
Veronica Hackethal, MD
A new study has found that patients with neuropsychiatric systemic lupus erythematosus have 3 times increased risk of death, and this risk increases to over 7 times higher in patients with focal CNS symptoms.
While migraine is distinct from stroke in its gradual onset and lack of focal motor weakness, it is also a predisposing factor for childhood stroke. That can raise the question, “Is it another migraine or is it actually stroke this time?”
Do you know about these handheld noninvasive devices for acute migraines and for migraine prophylaxis? About CGRPs anticipating FDA approval?
Seizure risk can be increased by illicit drug use, withdrawal from alcohol, and opioids or benzodiazepines. Which non-neuro medications can increase seizure risk, even when taken as directed? Test your knowledge in this quiz.
New technology may help patients and providers assess changes in severity of Parkinson disease symptoms more objectively.
When and why were the Beers criteria set in place? Learn more in this quiz.
Findings from a new study indicate that compared with children who were not exposed to the drug, children with in utero exposure to sodium valproate have lower scores on national tests at age 7 years.
A study undertaken to evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine has led to an FDA extended indication.
Three cases. Three questions. Your diagnosis.